Michael Favet's most recent trade in NeuroPace Inc was a trade of 225,000 Common Stock done . Disclosure was reported to the exchange on Feb. 21, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NeuroPace Inc | Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 225,000 | 407,080 | - | 0 | Common Stock | |
| NeuroPace Inc | Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 310,160 | 310,160 | - | - | Stock Option (Right to Buy) | |
| NeuroPace Inc | Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 155,080 | 182,080 | - | 0 | Common Stock | |
| NeuroPace Inc | Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 54,000 | 54,000 | - | - | Stock Option (Right to Buy) | |
| NeuroPace Inc | Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 27,000 | 27,000 | - | 0 | Common Stock | |
| NeuroPace Inc | Michael Favet | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.03 per share. | 26 Apr 2021 | 15,385 | 22,947 | - | 0.0 | 462 | Common Stock |
| NeuroPace Inc | Michael Favet | Director, Chief Executive Officer | 26 Apr 2021 | 7,562 | 7,562 | - | 0 | Common Stock | ||
| NeuroPace Inc | Michael Favet | Director, Chief Executive Officer | 26 Apr 2021 | 7,219 | 0 | - | - | Series B Preferred Stock | ||
| NeuroPace Inc | Michael Favet | Director, Chief Executive Officer | 26 Apr 2021 | 343 | 0 | - | - | Series A Preferred Stock |